Peregrine Ventures, an Israeli med-tech venture capital firm, closed its fourth fund, Peregrine 4, at $115m.
Their partners include some of the leading institutional and private equity investors from Israel, the United States, Europe and Australia.
Peregrine 4 will continue to invest in early stage and late stage rounds of medical technology startups.
The firm now has over $200 million under management, and an equal amount available for co-investment, follow-on, and late stage investments in its portfolio companies from Peregrine 1, 2, and 3.
Founded in 2001 and led by Eyal Lifschitz, Boaz Lifschitz (founding partners), Lior Shahory, Tamir Tal, David Eldar and Tal Carasso, Peregrine Ventures has made medical, biotech, and life science investments in Israel and completed 10 exits totaling more than $2 billion in cumulative value.
Exits include Valtech, Neovasc, B-Balloon, Eximo and Rocketick.
Peregrine Ventures also owns and operates the Incentive Incubator.
FinSMEs
09/12/2019